Sanofi Reports Solid Q4, Plans Share Buyback and Outlines Growth Path
Key Results:
* Q4 profit in line with estimates
* Business operating income decreased 7.7% to €2.08 billion
* Dupixent sales surged 16% to €3.46 billion
* Beyfortus sales more than doubled to €841 million
* Vaccines sales grew 10.8% to €2.18 billion
Strategic Moves:
* Plans to buy back €5 billion in shares this year
* Aiming for mid-to-high single-digit sales growth by 2025
* Transitioning to a pure-play drugmaker
* Nearing completion of sale of 50% stake in consumer health business to Clayton Dubilier & Rice
Analyst Commentary:
* Sales growth impacted by fewer business days in the quarter
* Investor expectations high for Dupixent after its expanded indication
* Beyfortus sales outpaced estimates, indicating strong demand
* Vaccines sales continue to contribute significantly to overall performance